Published in Blood on January 18, 2007
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood (2008) 1.52
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
Applications of microarray technology to Acute Myelogenous Leukemia. Cancer Inform (2008) 1.38
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia (2011) 1.25
Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem (2008) 1.21
Epigenetics in acute myeloid leukemia. Semin Oncol (2008) 1.16
Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes. Nucleic Acids Res (2011) 1.15
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. J Clin Invest (2012) 1.14
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia (2011) 1.09
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant (2011) 1.09
C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A (2010) 1.09
The many faces of C/EBPδ and their relevance for inflammation and cancer. Int J Biol Sci (2013) 1.06
Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells. J Biol Chem (2011) 1.03
The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells. PLoS One (2012) 1.03
Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia (2013) 1.00
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells. Mol Cell Biol (2011) 0.97
CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage. Proc Natl Acad Sci U S A (2010) 0.94
Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer (2010) 0.93
Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg (2011) 0.93
Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis. J Cancer Res Clin Oncol (2011) 0.92
Identification and characterization of CCAAT/Enhancer Binding proteindelta (C/EBPdelta) target genes in G0 growth arrested mammary epithelial cells. BMC Mol Biol (2008) 0.91
Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics (2010) 0.91
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest (2015) 0.90
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Med (2014) 0.89
Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res (2011) 0.89
PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery. J Biol Chem (2008) 0.86
CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis. Oncotarget (2015) 0.86
Epigenetic modifications unlock the milk protein gene loci during mouse mammary gland development and differentiation. PLoS One (2013) 0.86
CCAAT/Enhancer Binding Protein-delta (C/EBP-delta) regulates cell growth, migration and differentiation. Cancer Cell Int (2010) 0.85
Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res (2010) 0.84
Quantitative profiling of chromatome dynamics reveals a novel role for HP1BP3 in hypoxia-induced oncogenesis. Mol Cell Proteomics (2014) 0.82
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia (2015) 0.79
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer (2012) 0.79
The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell Death Dis (2014) 0.79
CCAAT-enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Lab Invest (2013) 0.79
C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. Oncogenesis (2014) 0.78
Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy. J Biol Chem (2014) 0.78
The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica (2010) 0.78
MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect. Oncotarget (2016) 0.78
Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Res (2015) 0.77
Genomic analysis of the role of transcription factor C/EBPδ in the regulation of cell behaviour on nanometric grooves. Biomaterials (2012) 0.77
Deficiency of CCAAT/enhancer binding protein family DNA binding prevents malignant conversion of adenoma to carcinoma in NNK-induced lung carcinogenesis in the mouse. Mol Cancer (2012) 0.76
Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness. Adv Hematol (2015) 0.75
Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget (2017) 0.75
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Comparative genome sequencing of Escherichia coli allows observation of bacterial evolution on a laboratory timescale. Nat Genet (2006) 4.44
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol (2011) 4.18
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol (2004) 3.84
Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol (2002) 3.08
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood (2010) 2.80
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79
Association testing by DNA pooling: an effective initial screen. Proc Natl Acad Sci U S A (2002) 2.79
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood (2012) 2.69
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell (2009) 2.42
Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell (2009) 2.39
Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol (2005) 2.36
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood (2012) 2.27
Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2009) 2.26
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol (2011) 2.26
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A (2009) 2.25
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A (2004) 2.11
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood (2007) 1.99
MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol (2003) 1.99
RNase T1 mediated base-specific cleavage and MALDI-TOF MS for high-throughput comparative sequence analysis. Nucleic Acids Res (2003) 1.99
Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat (2014) 1.98
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol (2004) 1.95
High-throughput MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res (2004) 1.92
Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci U S A (2008) 1.91
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood (2009) 1.90
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res (2003) 1.87
Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med (2009) 1.80
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78
Automated genotyping using the DNA MassArray technology. Methods Mol Biol (2002) 1.77
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol (2009) 1.73
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69